Macro Dragon: Preview WK #7 + Virus Update... Macro Dragon: Preview WK #7 + Virus Update... Macro Dragon: Preview WK #7 + Virus Update...

Macro Dragon: Preview WK #7 + Virus Update...

Macro 1 minute to read
Kay Van-Petersen

Global Macro Strategist

Summary:  Macro Dragon takes a preview of the upcoming WK 7, whilst checking in on the coronavirus. Don't forget its super Friday with jobs data due out of both the US & Canada - will be interesting to see if expectations are met, given how strong US ISM mfg. & non-mfg. have been this wk & just general bullish euphoria!


(These are solely the views & opinions of KVP, & do not constitute any trade or investment recommendations. By the time you synthesize this, things may have changed.)

2020-Feb-07

 

Macro Dragon: Preview WK #7 & Virus Update...

 

Preview of WK 7 & Thoughts…

  • Central bank wise, we have decision out of New Zealand (rates expected to be held at 1.00%) & Mexico (Rates expected to be cut to 7.00% from 7.25%). There is quite a bit of Fed speak, with Powell set to testify before the Senate banking Panel. We’ll also be hearing from RBA’s Lowe & Norges Bank’s Olsen.
  • Econ wise, CPI & PPI out of China, alongside loan data are likely to be ignored given the focus on the virus. We do also have CPI & retail sales out of the US, that is likely to be very much not ignored. Lastly IP & Flash GDP data out of Europe will be key.
  • Lastly for WK 7, it will be interesting to see if the New Hampshire primaries (Tue Feb 11 US time) will be just a touch better than the cluster %&#! that was the Iowa Caucuses – which likely resulted in Trump being the real winner & Peter-B getting some wind knocked out of his sail. Speaking of which, KVP may owes Vega some mula… as its looking “skin of teeth” close between “The Bern” & “Buddha Pete”. Looks like we have a recount in order.
  • Later today, don’t forget NFP 163k e 145k p, AHE 3.0%e 2.9%p & U/R 3.5% e/p – can imagine post those big beats on ISMs Mfg & Non-Mfg. earlier this wk, that it better be stellar numbers, as in-line to misses may take some starch out the market as we go into the wkd. As per last Fri, we’d likely see a big jump in confirmed cases globally & in China as we get back after it on Mon morning.

2019-nCoV Update Fri Asia Mrn 7 Feb…

Quick update & thoughts on the Virus since our Thu check in:

  • As of this Fri Asia morning, the  figures are 31,028 (28,276 +10% DoD, lower than yest’ +15%) confirmed cases, +636 (565) deaths & c. +1,507 (1,150) recovered. KVP reckons closer conservative number of infected now is likely +50,000 to 100,000 on the mainland… & before it is all over we are likely going to be well in the 6 figures… if we are not already there. Likewise, likely real numbers internationally are much higher, because quite simply there are a lot of countries & entire continents that are just not set up to screen for (which we know is a lot probability anyway), let alone contain & treat the confirmed cases. Seriously even the countries than can do these things, are not necessarily executing on them as they should.  
  • If there is only one thing you can read today, make time for this excellent perspective piece from a Linked-In post by Mario Cavolo. Cavolo is a US expat whose home for the last few decades has been China. The piece does help give a reset of the villainization that China & people of Chinese heritage (so not just mainland Chinese) have been going through around the world – post the outbreak of this virus. The author points out how there was another virus outbreak in the US, USA 2009 H1N1 Virus (swine flu), that lead to close to +300,000 & over 60m Americans infected (& over 760m globally) – yet there was no immediate government response, there was no shutting down the virus’s ground zero, nor closure of flights, nor scapegoating of the US.
  • Point here is not that 2019-nCoV is equal to 2009 H1N1 virus, but their treatment by the vast majority of global media outlets & the west are skewed so viscerally. Part of these may also be that social media & social network platforms were nowhere near as prevalent today, as they were 10yrs ago. It does suggest that we should stop & think what would have happened/or would happen if there is a virus outbreak in our respective countries / communities.  
  • Think a key takeaway is what we have flagged on Macro Dragon from wk one of following the Virus – the data in China, unfortunately is not likely to matter for markets in the near-term (which is dumb! But what can we say Mr/Mrs Market are quite the bi-polar individuals), especially for the US. It’s really going to be about the data abroad, as that will be construed as cleaner, more reliable & with less vested interests.  
  • So Japan is seriously breaking away from the pack internationally, they had 45 yest. & it looks like an additional 41 more cases have been found – the majority of these cases are tied to a floating Petri dish, which is a Cruise Ship called Yokohama that is in full lock-down (this is super lucky by the way for their respective countries). So we are standing at c. 86 cases in Japan at the moment (obviously not really “Japan”). SG +2 to 30. TH is 25. +4 in HK to 25. SK stays at 23, +1 in AU to 15, GER +1 to 13, US stays 12, TW +5 to 16, Vietnam +2 to 12 & Macau still at 10.
  • KVP is getting more towards the view that similar to the USA’s H1N1 Virus, that pretty much spread unchecked globally with zero consequences for the US – that we may just get to a point globally where we accept that 2019-nCoV is going to be here to stay. Again, this is not a walking dead or head exploding mutagen. This is a virus that is of the same strain as the common cold or the flu – the greatest risks are to those with weak immune systems and/or have other on going medical conditions. And just like how you get the cold or the Flu, rest & recuperation – helping the body’ own immune system is generally the pathway to recovery. Again this is based on the mixed information & data that we know today.
  • Still not yet sure we are close to peak hysteria & need for education globally on this. For once, hope to be wrong here.
  • One thing is for sure, the market currently does not care nor is it pricing the fact that China is going to take a lot longer to get back to running at its usual run-rate.
  • Just amazed that the Macau names continue to rally even post their initial technical bounce & post the government suspending operations for half a month (which would not surprise KVP if it was extended). Even if we were to cure the virus overnight & halt all spread globally, who is going to gamble next wkd in Macau? There is a fear to taboo element here that will take time to work its way out of people’s psyche, which will again make it that more challenging for tourism linked to China & from China.  

-

 

Have a fantastic, gratitude & abundant filled wkd ahead everyone, stay healthy as well as keep your mind open to profitable & abundant opportunities. Life happens for us, not to us.  

Namaste,


Namaste,

-KVP

-

Some Anchor Pieces from #SaxoStrats:

Disclaimer

The Saxo Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo or its affiliates.

Saxo Capital Markets HK Limited
19th Floor
Shanghai Commercial Bank Tower
12 Queen’s Road Central
Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R

Saxo Capital Markets HK Limited (“Saxo”) is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo holds a Type 1 Regulated Activity (Dealing in Securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged Foreign Exchange Trading); Type 4 Regulated Activity (Advising on Securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products may result in your losses exceeding your initial deposits. Saxo does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo does not take into account an individual’s needs, objectives or financial situation. Please click here to view the relevant risk disclosure statements.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-hk/about-us/awards.

The information or the products and services referred to on this site may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and services offered on this website are not directed at, or intended for distribution to or use by, any person or entity residing in the United States and Japan. Please click here to view our full disclaimer.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc. Android is a trademark of Google Inc.